CASIRATI, ELIA
CASIRATI, ELIA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Estrogen–ER-α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women
2024 A. Cherubini, E. Casirati, S. Pelusi, L. Valenti
PNPLA3 P.I148M VARIANT INCREASES LIPID DROPLETS NUMBER AND SIZE IN PATIENT-DERIVED LIVER ORGANOIDS
2024 E. Casirati
Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19]
2024 F. Salomone, R. Pipitone, M. Longo, F. Malvestiti, A. Amorini, A. Distefano, E. Casirati, E. Ciociola, N. Iraci, L. Leggio, R. Zito, N. Vicario, C. Saoca, V. Männistö, J. Pihlajamäki, S. Qadri, H. Yki-Järvinen, S. Romeo, G. Pennisi, D. Cabibi, G. Lazzarino, A. Fracanzani, P. Dongiovanni, L. Valenti, S. Petta, G. Volti, S. Grimaudo
Editorial: Unveiling new horizons for liver steatosis genetic variants beyond hepatocellular carcinoma diagnosis - exploring the potential of HSD17B13 inhibition
2023 L. Valenti, E. Casirati
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
2023 A. Cherubini, M. Ostadreza, O. Jamialahmadi, S. Pelusi, E. Rrapaj, E. Casirati, G. Passignani, M. Norouziesfahani, E. Sinopoli, G. Baselli, C. Meda, P. Dongiovanni, D. Dondossola, N. Youngson, A. Tourna, S. Chokshi, E. Bugianesi, E. Study Investigators, S. DELLA TORRE, D. Prati, S. Romeo, L. Valenti
Numerical refractive index correction for the stitching procedure in tomographic quantitative phase imaging
2022 P. Stępień, M. Ziemczonok, M. Kujawińska, M. Baczewska, L. Valenti, A. Cherubini, E. Casirati, W. Krauze
PNPLA3 as a therapeutic target for fatty liver disease : the evidence to date
2021 A. Cherubini, E. Casirati, M. Tomasi, L.V.C. Valenti
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
2021 C. Bianco, E. Casirati, F. Malvestiti, L. Valenti